Low bleeding and thromboembolic risk with continued dabigatran during cardiovascular interventions: the GLORIA-AF study

CONCLUSIONS: More than two thirds of the interventions were performed with uninterrupted dabigatran therapy, of which most were AF-cardioversions. Uninterrupted dabigatran therapy was associated with low major bleeding and stroke/systemic embolism risk, supporting the favourable safety and effectiveness profile of dabigatran in clinical practice-based settings.PMID:34120814 | DOI:10.1016/j.ejim.2021.05.020

Source: European Journal of Internal Medicine - June 14, 2021 Category: Internal Medicine Authors: Sake J van der Wall Gregory Y H Lip Christine Teutsch Oskars Kalejs Philippe Lyrer Christian Hall Sergio J Dubner Hans-Christoph Diener Jonathan L Halperin Chang Sheng Ma Kenneth J Rothman Kristina Zint Dongmei Zhai Menno V Huisman GLORIA-AF Investigators Source Type: research